Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Glioma 1Fallopian Tube Mucinous Adenocarcinoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillary renal cell carcinoma, sporadic × Contrast Media × 90 days × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡